Economic modeling of HIV treatments

Current Opinion in HIV and AIDS

Volumn 5, Issue 3, 2010, Pages 242-248

  Simpson, Kit N ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cost effectiveness; Economics; HIV; Modeling

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; LOPINAVIR PLUS RITONAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL MODEL; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; REVIEW; RISK FACTOR; SCALE UP; SCREENING; SOUTH AFRICA; SURVIVAL TIME; VIRUS LOAD;

ANTI-HIV AGENTS; CHEMOPREVENTION; HIV INFECTIONS; HUMANS; MASS SCREENING; MICROBIAL SENSITIVITY TESTS; MODELS, ECONOMIC; SOUTH AFRICA;

EID: 77951090496     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283384aed     Document Type: Review

References (46)

1. Simpson KN. Modeling with clinical trial data: getting from the data researchers have to the data decision makers need. Drug Inform J 1995; 29:1431-1440.
2. Simpson KN. Design and assessment of cost effectiveness studies in AIDS populations. J Acquir Immune Defic Syndr 1995; 10 (Suppl 4):S28-S32.
3. Brennan A, Akehurst R. Modeling in health economic evaluation. PharmacoEconomics 2000; 17:445-459.
4. Mauskopf JA. Meeting the NICE requirements: a Markov model approach. Value Health 2000; 5:297-1293
5. Lim ME, Bowen JM, O'Reilly, et al. The impact of the 1997 Canadian guidelines on the conduct of Canadian-based economic evaluations in the published literature. Value Health 2010; 13 [published ahead of print accessed 12/21/2009].
6. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good research practice for decision analytic modeling in healthcare evaluation: report of the ISPOR task force on good research practices: modeling studies. Value Health 2003; 6:9-17.
7. Weinstein MC. Recent developments in decision-analytic modeling for economic evaluation. PharmacoEconomics 2006; 24:1043-1043
8. Shulpher M, Fenwick E, Claxton K. Assessing quality in decision analytic cost-effectiveness models: a suggested framework and example of application. PharmacoEconomics 2000; 17:461-477.
9. Schulman KA, Lynn LA, Glick HA, et al. Cost-effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. Ann Intern Med 1991; 114:798-802.
10. Simpson K, Hatziandreu EJ, Andersson F, et al. Cost effectiveness of antiviral treatment with zalcitabine plus zidovudine for AIDS patients with CD4+ counts less than 300/ml in 5 European countries. PharmacoEconomics 1994; 6:553-562.
11. Chancellor J, Hill A, Simpson K, Yule M. Cost effectiveness of 3TC and ZDV in patients with HIV-disease. PharmacoEconomics 1997; 12:1-13.
12. Mauskopf JA, Tolson JM, Simpson KN, et al. The impact of zidovudine-based triple combination therapy on an AIDS drug assistance program. J Acquir Immune Defic Syndr 2000; 23:302-313.
13. Freedberg KA, Losina E, Weinstein MC, et al. The cost-effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344:824-831. (Pubitemid 32222162)
14. Simpson KN, Voit EO, Goodman R, Chumney ECG. Estimating the social and economic benefits of pharmaceutical innovations: modeling clinical trial results in HIV-disease. Res Hum Capital Dev 2001; 14:175-198.
15. Simpson KN, Luo MP, Chumney ECG, et al. Cost effectiveness of using lopinavir vs. nelfinavir as the first highly active antiretroviral therapy regimen for HIV infection. HIV Clin Trials 2004; 5:294-304.
16. Mauskopf J, Kitahata M, Kauf T, et al. HIV antiretroviral treatment: early versus later. Acquir Immune Defic Syndr 2005; 39:562-569.
17. Goldie SJ, Yazdanpanah Y, Losina E, et al. Cost-effectiveness of HIV treatment in resource-poor settings: the case of Cote d'Ivoire. N Engl J Med 2006; 355:1141-1153.
18. Simpson KN, Strassburger A, Jones WJ, et al. Comparison of Markov model and discrete event simulation (DES) techniques for HIV disease. PharmacoEconomics 2009; 27:159-165.
19. Walensky RP, Wolf LL, Fofana MO, et al. When to start antiretroviral therapy in resource-limited settings. Ann Intern Med 2008; 151:157-166.
20. Schackman BR, Scott CA, Walensky RP, et al. The cost-effectiveness of HLA-B-5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 2008; 22:2025-2037.
21. Paltiel AD, Freedberg KA, Scott CA, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost- effectiveness. Clin Infect Dis 2009; 48:806-815.
22. Walensky RP, Wood R, Weinstein MC, et al. Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis 2009; 197:1324-1332. Shows the economic and health outcomes of different scale-up scenarios.
23. Simpson KN, Roberts G, Hicks CB, Finnern HW. Cost-effectiveness of tipranavir in treatment experienced HIV patients in the US. HIV Clin Trials 2008; 9:225-237.
24. Simpson KN, Rajagopalan R, Dietz B. Cost-effectiveness analysis of lopinavir/ ritonavir and atazanavir+ritonavir regimens in the CASTLE study. Adv Ther 2009; 26:185-193.
25. Beard J, Feeley F, Rosen S. Economic and quality of life of antiretroviral therapy for HIV/AIDS in developing countries: a systematic review. AIDS Care 2009; 21:1343-1356.
26. Lord J, Laking G, Fischer A. Nonlinearity in the cost-effectiveness frontier. Health Econ 2006; 15:565-577.
27. Barton GR, Briggs AH, Fenwick EAL. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost- effectiveness acceptability frontier (CEAF), and the expected value of perfect information (EVPI). Value Health 2008; 11:886-897.
28. Zarkin GA, Bray JW, Aldridge A, et al. Cost and cost-effectiveness of the COMBINE study in alcohol-dependent patients. Arch Gen Psychiatry 2008; 65:1214-1221.
29. Hill A, Wood E. Balancing effectiveness and access to HIV treatment in the developing world. AIDS 2007; 21:361-363.
30. Hill A, Hemmett L, Wilson B. Analysis of cost by CD4 count category for the darunavir 600/100mg bid and control protease inhibitor arms of the POWER 1 and 2 trials. HIV Clin Trials 2007; 8:303-310.
31. Hill A, Gebo K. Predicting HIV care costs using CD4 counts from clinical trials. Am J Mang Care 2007; 13:524-528.
32. Rosa RSl, Herrera L, Moreno S. Cost-effectiveness analysis of emtricitabine/ tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral- naïve, HIV-infected patients. Clin Therapeut 2008; 30:372-381.
33. Linas BP, Losina E, Rockwell A, et al. Improving outcomes in state AIDS Drug Assistance programs. J Acquir Immune Defic Syndr 2009; 51:513-521.
34. Mauskopf J, Brogan AJ, Malmberg C, Hwang P. Cost-effectiveness of darunavir for the management of HIV-infected, treatment-experienced adults in Canada. Poster Presented at the 16th Annual Canadian Conference on HIV/AIDS Research, April 2007.
35. McKeage K, Perry CM, Keam SJ. Darunavir: a review of its use in the management of HIV infection in adults. Drugs 2009; 69:477-503.
36. Darunavir/ritonavir dominates most other PI/ritonavir combinations. PharmacoEconomics and Outcomes News: 14 November 2009 591 p6.
37. Public Summary Document November 2008 PBAC Meeting. Product: Maraviroc. Sponsor: Pfizer Australia Pty Ltd. http://www.health.gov.au/ internet/main/publishing.nsf/Content/health-pbs-general-outcomes-full.htm accessed 12/1/2009.
38. Scottish Medicines Consortium (SMC) Published 08 December 2008. Atazanavir, 300 mg capsules (Reyataz1) No. (520/08) ADVICE: following a full submission. www.scottishmedicines.org.uk accessed 12/1/2009.
39. New Medicines Group. Preliminary Appraisal Report: Darunavir (Prezista 1) in treatment-naïve patients, November 2009. http://www.wales.nhs.uk/ sites3/page.cfm?orgid=371&pid=35401 accessed 12/20/2009.
40. Mocroft A, Ruiz L, Reiss P, et al. Virological rebound after suppression on highly active antiretroviral therapy. AIDS 2001; 17:1741-1751.
41. Leen C, Thureson LC, Heeg B, et al. Cost-effectiveness of atazanavir/r vs. lopinavir in Scotland. 15th Annual Conference of BHIVA, April 1-2, 2009, Poster.
42. Franks P, Hammer J, Fryback DG. Relative disutilities of 47 risk factors and conditions assessed with seven preference-based health status measures in a national US sample. Med Care 2006; 44:478-485.
43. Kauf TL, Roskell N, Shearer A, et al. A predictive model of health state utilities for HIV patients in the modern era of highly active antiretroviral therapy. Value Health 2008; 11:1144-1153.
44. Granich RM, Gilks CF, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373: 48-57.
45. Simpson KN, Luo MP, Chumney EC, et al. Cost effectiveness of lopinavir/r vs. atazanavir in treating antiretroviral-naïve patients: modeling the combined effects of HIV and heart disease. 7th International HIV Congress on Drug Therapy in HIV Infection. November 17, 2004, Glasgow, UK. Poster.
46. Simpson KN, Rajagopalan R, Dietz B, et al. Economic modeling of the combined effects of HIV-disease, heart disease and lipoatrophy based on ACTG 5142 trial data. Ninth International Congress on Drug Therapy in HIV Infection, November 9, 2008, Glasgow, UK. #P312.